Roivant Sciences $150 million equity offering
We advised the company on its debut SEC-registered primary and secondary offering
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Akoya Biosciences $50 million at-the-market program
The common stock is listed on the Nasdaq Global Select Market
Elevance Health $1.8 billion senior notes offering
The investment-grade notes are due 2025, 2032 and 2052
NextGen Healthcare $275 million convertible senior notes offering
The 3.75% convertible notes are due 2027
Recursion Pharmaceuticals $150 million private placement
We advised the placement agents on the private placement of common stock
Prime Medicine $175 million IPO
The shares are listed on the Nasdaq Global Market
Denali Therapeutics $316 million follow-on offering
The shares are listed on the Nasdaq Global Select Market
European Biotech Acquisition $200 million combination with Oculis
We are advising European Biotech Acquisition Corp. on its deSPAC transaction
Immatics $110 million follow-on offering
We advised Immatics on the offering of shares
Gamida Cell $20 million follow-on offering
The shares are listed on the Nasdaq Global Select Market